Sarah Tabrizi

Sarah Joanna Tabrizi
FMedSci FRS
Sarah Tabrizi in July 2024
Born
London, UK
Alma materHeriot-Watt University
University of Edinburgh
University College London
Known forResearch into neurodegeneration, particularly Huntington's disease
SpouseMichael Nath
AwardsFellowship of the Academy of Medical Sciences, 2014
MRC Millennium Medal, 2022
Fellowship of the Royal Society, 2024
National Academy of Medicine, 2024
Scientific career
FieldsNeuroscience
InstitutionsUCL Institute of Neurology;
National Hospital for Neurology and Neurosurgery
ThesisMitochondrial dysfunction in the pathogenesis of neurodegeneration (2000)
Websitehttps://www.ucl.ac.uk/ion/research/research-centres/hd-centre

Sarah Joanna Tabrizi FMedSci FRS is a British neurologist and neuroscientist in the field of neurodegeneration, particularly Huntington's disease. She is a Professor and Joint Head of the Department of Neurodegenerative Diseases[1] at the UCL Institute of Neurology; the founder and Director of the UCL Huntington's Disease Centre; a Principal Investigator at the UK Dementia Research Institute at UCL; and an Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London, where she established the Multidisciplinary Huntington's Disease Clinic.[2][3][4] The UCL Huntington’s Disease Centre was officially opened on 1 March 2017 by UCL President and Provost Michael Arthur.[5]

Education and career

Tabrizi graduated with a first-class degree in biochemistry from Heriot-Watt University in 1986 and an MB ChB from the University of Edinburgh in 1992, where she graduated with the Gold Medal (Ettles Scholar) for the most distinguished medical graduate.[2] She obtained a PhD at University College London in 2000.[6] During her time as a trainee neurologist at the National Hospital for Neurology and Neurosurgery (NHNN), Queen Square, Sarah worked for Professors Anita Harding and David Marsden, both of whom would make a lasting impression on her.[7] She undertook an MRC Clinical Training Fellowship PhD studying mitochondrial dysfunction in neurodegeneration with Tony Schapira and Gillian Bates from 1996 to 1999 then obtained a Department of Health National Clinician Scientist Fellowship at the UCL Institute of Neurology in 2002 to work with John Collinge and Charles Weissmann on prion cell biology. She was promoted to UCL Clinical Senior Lecturer and Honorary Consultant Neurologist in 2003, to Reader in 2007 and Full Professor in 2009.[8]

Research

Tabrizi is distinguished for her work on mechanisms of cellular neurodegeneration[9][10][11][12][13] and in particular Huntington's disease mechanistic pathobiology, novel therapeutics, biomarkers, outcome measures and first in human clinical trials.[14][15] Amongst her achievements, she has identified key pathogenic mechanisms in cellular degeneration in prion disease,[16][17][18] identified a key role for the innate immune system in the pathogenesis of Huntington’s disease,[19] published the first assay of the mutant HD protein,[20] and designed and led two major, international, influential research initiatives, TRACK-HD and Track-On HD. To date these studies have yielded fundamental new insights into the preclinical phase of neurodegeneration in Huntington’s disease including identifying predictors of disease onset,[21][22][23][24][25][26][27] progression, evidence of brain compensation and plasticity and neurobiological changes occurring twenty years before predicted disease onset, and her work established a battery of clinical trial outcome measures now being used in global clinical trials.[28][21][22][23][24][29] In 2017, her work identified an important new genetic modifier of disease progression in Huntington’s disease (MSH3, a mismatch repair protein), which has opened up new avenues of research into targeting DNA repair pathways as possible therapeutics for Huntington’s disease.[30][31][32] A major focus of her research now is to build understanding of how different DNA repair mechanisms are involved in modifying the development of Huntington’s disease. This knowledge to develop novel therapeutic approaches that could stop, slow down or reverse the progression of the disease by targeting the somatic expansion of the CAG repeat tract.[33][34][35]

Tabrizi gave a keynote presentation at the 2016 Google Zeitgeist Minds conference about her research, and the prospect of gene silencing for neurodegenerative disease.[36] She was the global lead Clinical Investigator for the first clinical trial of a 'gene silencing' or huntingtin-lowering antisense oligonucleotide (ASO) drug in Huntington's disease patients. The announcement of the ‘top line’ results from the Phase 1b/2a safety trial in December 2017 received widespread national and international media coverage and was covered in features by BBC News,[37] Guardian[38] and Nature.[39] In May 2019 the full results were published in The New England Journal of Medicine.[40][41]

The potential of antisense oligonucleotides to treat neurodegenerative diseases was reviewed by Tabrizi in Science in 2020.[42] Tabrizi is currently working on several different approaches to treat Huntington’s disease, including testing novel ASOs targeting MSH3 to slow CAG repeat expansion, allele-selective approaches to target mutant HTT only, and new gene therapy approaches targeting the mutant HD gene.[43]

In 2020, Tabrizi published the Huntington’s Disease Young Adult Study (HD-YAS) studying premanifest HD gene carriers approximately 24 years from predicted onset of clinical symptoms using advanced neuroimaging, detailed cognitive testing and biofluid collection.[44] The cohort did not show any clinically meaningful functional impairment, yet there was evidence of elevated levels of neurofilament light protein, suggestive of very early neuronal damage, in those closest to expected symptom onset. HD-YAS will provide critical information on the very earliest signs of neurodegeneration, identifying a time at which a therapy could potentially be introduced to delay or even ultimately prevent the onset of clinical symptoms in HD.[44] This approach has implications beyond HD, providing a model for disease prevention in neurodegeneration and this work continues to be of major interest in the Tabrizi lab.[45]

In 2022, alongside colleagues at the HD Regulatory Science Consortium and CHDI, Tabrizi developed a novel staging framework, the Huntington’s Disease Integrated Staging System (HD-ISS), that assesses the progression of disease from birth.[46] Similar to the cancer staging system, the HD-ISS defines HD in four stages, from 0-3, and also biologically defines the disease as the presence of the HTT CAG repeat mutation. This will allow clinical trials much earlier in course of the disease process, and well in advance of when people show signs and symptoms of the disease, allowing the possibility of disease prevention in the future.

Tabrizi was the subject of profile articles in The Lancet in 2012 and The Lancet Neurology in 2017.[47][48]

As of May 2024, Tabrizi had authored over 380 publications, with over 39,000 citations for her research.[49]

Awards and honours

Personal life

Tabrizi lives in London with her husband, the author Michael Nath.[6]

References

  1. ^ "Department of Neurodegenerative Disease". UCL Institute of Neurology. 2 August 2018.
  2. ^ a b "Iris View Profile". IRIS - UCL. Retrieved 5 May 2016.
  3. ^ "UCL Huntington's Disease Research". hdresearch.ucl.ac.uk.
  4. ^ "Prof Sarah Tabrizi". www.uclh.nhs.uk. Archived from the original on 31 August 2022. Retrieved 5 May 2016.
  5. ^ "The UCL Huntington's Disease Centre opens". 2 March 2017.
  6. ^ a b c "Who's Who 2016 - Tabrizi, Prof. Sarah Joanna". Who's Who 2016. Retrieved 6 May 2016.
  7. ^ Shetty, Priya (2012). "Sarah Tabrizi: Tracking Huntington's disease". The Lancet. 379 (9831): 2043. doi:10.1016/S0140-6736(12)60884-8. PMID 22656876. S2CID 40222846.
  8. ^ "Professor Sarah J Tabrizi". UCL Iris.
  9. ^ Deriziotis, Pelagia; André, Ralph; Smith, David M; Goold, Rob; Kinghorn, Kerri J; Kristiansen, Mark; Nathan, James A; Rosenzweig, Rina; Krutauz, Dasha; Glickman, Michael H; Collinge, John; Goldberg, Alfred L; Tabrizi, Sarah J (8 July 2011). "Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry". The EMBO Journal. 30 (15): 3065–3077. doi:10.1038/emboj.2011.224. PMC 3160194. PMID 21743439.
  10. ^ Kristiansen, Mark; Messenger, Marcus J.; Klöhn, Peter-Christian; Brandner, Sebastian; Wadsworth, Jonathan D. F.; Collinge, John; Tabrizi, Sarah J. (18 November 2005). "Disease-related Prion Protein Forms Aggresomes in Neuronal Cells Leading to Caspase Activation and Apoptosis". Journal of Biological Chemistry. 280 (46): 38851–38861. doi:10.1074/jbc.M506600200. PMID 16157591.
  11. ^ Kristiansen, Mark; Deriziotis, Pelagia; Dimcheff, Derek E.; Jackson, Graham S.; Ovaa, Huib; Naumann, Heike; Clarke, Anthony R.; van Leeuwen, Fijs W.B.; Menéndez-Benito, Victoria; Dantuma, Nico P.; Portis, John L.; Collinge, John; Tabrizi, Sarah J. (April 2007). "Disease-Associated Prion Protein Oligomers Inhibit the 26S Proteasome". Molecular Cell. 26 (2): 175–188. doi:10.1016/j.molcel.2007.04.001. hdl:11858/00-001M-0000-0012-2650-5. PMID 17466621.
  12. ^ Goold, R.; Rabbanian, S.; Sutton, L.; Andre, R.; Arora, P.; Moonga, J.; Clarke, A.R.; Schiavo, G.; Jat, P.; Collinge, J.; Tabrizi, S.J. (19 April 2011). "Rapid cell-surface prion protein conversion revealed using a novel cell system". Nature Communications. 2 (1): 281–. Bibcode:2011NatCo...2..281G. doi:10.1038/ncomms1282. PMC 3104518. PMID 21505437.
  13. ^ McKinnon, Chris; Goold, Rob; Andre, Ralph; Devoy, Anny; Ortega, Zaira; Moonga, Julie; Linehan, Jacqueline M.; Brandner, Sebastian; Lucas, José J.; Collinge, John; Tabrizi, Sarah J. (8 December 2015). "Prion-mediated neurodegeneration is associated with early impairment of the ubiquitin–proteasome system". Acta Neuropathologica. 131 (3): 411–425. doi:10.1007/s00401-015-1508-y. PMC 4752964. PMID 26646779.
  14. ^ Shetty, Priya (2012). "Sarah Tabrizi: Tracking Huntington's disease". The Lancet. 379 (9831): 2043. doi:10.1016/S0140-6736(12)60884-8. PMID 22656876. S2CID 40222846.
  15. ^ Mohammadi, Dara (July 2015). "Fast-forwarding treatment for neurodegenerative disorders". The Lancet Neurology. 14 (7): 687–688. doi:10.1016/S1474-4422(15)00110-6. PMID 26067120.
  16. ^ Deriziotis, Pelagia; André, Ralph; Smith, David M; Goold, Rob; Kinghorn, Kerri J; Kristiansen, Mark; Nathan, James A; Rosenzweig, Rina; Krutauz, Dasha; Glickman, Michael H; Collinge, John (8 July 2011). "Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry". The EMBO Journal. 30 (15): 3065–3077. doi:10.1038/emboj.2011.224. ISSN 0261-4189. PMC 3160194. PMID 21743439.
  17. ^ Kristiansen, Mark; Deriziotis, Pelagia; Dimcheff, Derek E.; Jackson, Graham S.; Ovaa, Huib; Naumann, Heike; Clarke, Anthony R.; van Leeuwen, Fijs W.B.; Menéndez-Benito, Victoria; Dantuma, Nico P.; Portis, John L. (April 2007). "Disease-Associated Prion Protein Oligomers Inhibit the 26S Proteasome". Molecular Cell. 26 (2): 175–188. doi:10.1016/j.molcel.2007.04.001. hdl:11858/00-001M-0000-0012-2650-5. PMID 17466621.
  18. ^ Kristiansen, Mark; Messenger, Marcus J.; Klöhn, Peter-Christian; Brandner, Sebastian; Wadsworth, Jonathan D. F.; Collinge, John; Tabrizi, Sarah J. (18 November 2005). "Disease-related Prion Protein Forms Aggresomes in Neuronal Cells Leading to Caspase Activation and Apoptosis". Journal of Biological Chemistry. 280 (46): 38851–38861. doi:10.1074/jbc.M506600200. ISSN 0021-9258. PMID 16157591.
  19. ^ Björkqvist, Maria; Wild, Edward J; Thiele, Jenny; Silvestroni, Aurelio; Andre, Ralph; Lahiri, Nayana; Raibon, Elsa; Lee, Richard V; Benn, Caroline L; Soulet, Denis; Magnusson, Anna; Woodman, Ben; Landles, Christian; Pouladi, Mahmoud A; Hayden, Michael R; Khalili-Shirazi, Azadeh; Lowdell, Mark W; Brundin, Patrik; Bates, Gillian P; Leavitt, Blair R; Möller, Thomas; Tabrizi, Sarah J (2008). "A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease". The Journal of Experimental Medicine. 205 (8): 1869–77. doi:10.1084/jem.20080178. PMC 2525598. PMID 18625748.
  20. ^ Weiss, Andreas; Träger, Ulrike; Wild, Edward J; Grueninger, Stephan; Farmer, Ruth; Landles, Christian; Scahill, Rachael I; Lahiri, Nayana; Haider, Salman; MacDonald, Douglas; Frost, Chris; Bates, Gillian P; Bilbe, Graeme; Kuhn, Rainer; Andre, Ralph; Tabrizi, Sarah J (2012). "Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression". Journal of Clinical Investigation. 122 (10): 3731–6. doi:10.1172/jci64565. PMC 3461928. PMID 22996692.
  21. ^ a b Tabrizi, Sarah J; Langbehn, Douglas R; Leavitt, Blair R; Roos, Raymund AC; Durr, Alexandra; Craufurd, David; Kennard, Christopher; Hicks, Stephen L; Fox, Nick C; Scahill, Rachael I; Borowsky, Beth; Tobin, Allan J; Rosas, H Diana; Johnson, Hans; Reilmann, Ralf; Landwehrmeyer, Bernhard; Stout, Julie C (2009). "Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data". The Lancet Neurology. 8 (9): 791–801. doi:10.1016/s1474-4422(09)70170-x. PMC 3725974. PMID 19646924.
  22. ^ a b Tabrizi, Sarah J; Scahill, Rachael I; Durr, Alexandra; Roos, Raymund AC; Leavitt, Blair R; Jones, Rebecca; Landwehrmeyer, G Bernhard; Fox, Nick C; Johnson, Hans; Hicks, Stephen L; Kennard, Christopher; Craufurd, David; Frost, Chris; Langbehn, Douglas R; Reilmann, Ralf; Stout, Julie C; TRACK-HD Investigators (2011). "Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: The 12-month longitudinal analysis". The Lancet Neurology. 10 (1): 31–42. doi:10.1016/s1474-4422(10)70276-3. PMID 21130037. S2CID 2602096.
  23. ^ a b Tabrizi, Sarah J; Reilmann, Ralf; Roos, Raymund AC; Durr, Alexandra; Leavitt, Blair; Owen, Gail; Jones, Rebecca; Johnson, Hans; Craufurd, David; Hicks, Stephen L; Kennard, Christopher; Landwehrmeyer, Bernhard; Stout, Julie C; Borowsky, Beth; Scahill, Rachael I; Frost, Chris; Langbehn, Douglas R; TRACK-HD investigators (2012). "Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: Analysis of 24 month observational data". The Lancet Neurology. 11 (1): 42–53. doi:10.1016/s1474-4422(11)70263-0. PMID 22137354. S2CID 34929053.
  24. ^ a b Tabrizi, Sarah J; Scahill, Rachael I; Owen, Gail; Durr, Alexandra; Leavitt, Blair R; Roos, Raymund A; Borowsky, Beth; Landwehrmeyer, Bernhard; Frost, Chris; Johnson, Hans; Craufurd, David; Reilmann, Ralf; Stout, Julie C; Langbehn, Douglas R (2013). "Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: Analysis of 36-month observational data". The Lancet Neurology. 12 (7): 637–49. doi:10.1016/s1474-4422(13)70088-7. PMID 23664844. S2CID 12204298.
  25. ^ Klöppel, Stefan; Gregory, Sarah; Scheller, Elisa; Minkova, Lora; Razi, Adeel; Durr, Alexandra; Roos, Raymund A.C; Leavitt, Blair R; Papoutsi, Marina; Landwehrmeyer, G. Bernhard; Reilmann, Ralf; Borowsky, Beth; Johnson, Hans; Mills, James A; Owen, Gail; Stout, Julie; Scahill, Rachael I; Long, Jeffrey D; Rees, Geraint; Tabrizi, Sarah J (2015). "Compensation in Preclinical Huntington's Disease: Evidence from the Track-On HD Study". eBioMedicine. 2 (10): 1420–9. doi:10.1016/j.ebiom.2015.08.002. PMC 4634199. PMID 26629536.
  26. ^ Gregory, Sarah; Long, Jeffrey D; Klöppel, Stefan; Razi, Adeel; Scheller, Elisa; Minkova, Lora; Papoutsi, Marina; Mills, James A; Durr, Alexandra; Leavitt, Blair R; Roos, Raymund A. C; Stout, Julie C; Scahill, Rachael I; Langbehn, Douglas R; Tabrizi, Sarah J; Rees, Geraint (2017). "Operationalizing compensation over time in neurodegenerative disease". Brain. 140 (4): 1158–1165. doi:10.1093/brain/awx022. PMC 5382953. PMID 28334888.
  27. ^ Gregory, Sarah; Long, Jeffrey D; Klöppel, Stefan; Razi, Adeel; Scheller, Elisa; Minkova, Lora; Johnson, Eileanoir B; Durr, Alexandra; Roos, Raymund A C; Leavitt, Blair R; Mills, James A; Stout, Julie C; Scahill, Rachael I; Tabrizi, Sarah J; Rees, Geraint; Coleman, A; Decolongon, J; Fan, M; Koren, T; Leavitt, B; Durr, A; Jauffret, C; Justo, D; Lehericy, S; Nigaud, K; Valabrègue, R; Roos, R; Hart, E P 't; Schoonderbeek, A; et al. (2018). "Testing a longitudinal compensation model in premanifest Huntington's disease". Brain. 141 (7): 2156–2166. doi:10.1093/brain/awy122. PMC 6022638. PMID 29788038.
  28. ^ Shetty, Priya (2012). "Sarah Tabrizi: Tracking Huntington's disease". The Lancet. 379 (9831): 2043. doi:10.1016/s0140-6736(12)60884-8. PMID 22656876. S2CID 40222846.
  29. ^ Arney, Kat (2018). "Improved metrics for Huntington's disease trials". Nature. 557 (7707): S46 – S47. Bibcode:2018Natur.557S..46A. doi:10.1038/d41586-018-05179-w. PMID 29844554. S2CID 256768548.
  30. ^ Moss, Davina J Hensman; Pardiñas, Antonio F; Langbehn, Douglas; Lo, Kitty; Leavitt, Blair R; Roos, Raymund; Durr, Alexandra; Mead, Simon; Holmans, Peter; Jones, Lesley; Tabrizi, Sarah J; Coleman, A; Santos, R Dar; Decolongon, J; Sturrock, A; Bardinet, E; Ret, C Jauff; Justo, D; Lehericy, S; Marelli, C; Nigaud, K; Valabrègue, R; Van Den Bogaard, SJA; Dumas, E M; Van Der Grond, J; t'Hart, EP; Jurgens, C; Witjes-Ane, M-N; Arran, N; et al. (2017). "Identification of genetic variants associated with Huntington's disease progression: A genome-wide association study" (PDF). The Lancet Neurology. 16 (9): 701–711. doi:10.1016/s1474-4422(17)30161-8. PMID 28642124. S2CID 588163.
  31. ^ Flower, Michael; Lomeikaite, Vilija; Ciosi, Marc; Cumming, Sarah; Morales, Fernando; Lo, Kitty; Hensman Moss, Davina; Jones, Lesley; Holmans, Peter; Monckton, Darren G.; Tabrizi, Sarah J. (1 July 2019). "MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1". Brain. 142 (7): 1876–1886. doi:10.1093/brain/awz115. ISSN 0006-8950. PMC 6598626. PMID 31216018.
  32. ^ Tabrizi, Sarah J.; Estevez-Fraga, Carlos; van Roon-Mom, Willeke M. C.; Flower, Michael D.; Scahill, Rachael I.; Wild, Edward J.; Muñoz-Sanjuan, Ignacio; Sampaio, Cristina; Rosser, Anne E.; Leavitt, Blair R. (July 2022). "Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities". The Lancet. Neurology. 21 (7): 645–658. doi:10.1016/S1474-4422(22)00121-1. ISSN 1474-4465. PMC 7613206. PMID 35716694.
  33. ^ Goold, Robert; Flower, Michael; Moss, Davina Hensman; Medway, Chris; Wood-Kaczmar, Alison; Andre, Ralph; Farshim, Pamela; Bates, Gill P; Holmans, Peter; Jones, Lesley; Tabrizi, Sarah J (15 February 2019). "FAN1 modifies Huntington's disease progression by stabilizing the expanded HTT CAG repeat". Human Molecular Genetics. 28 (4): 650–661. doi:10.1093/hmg/ddy375. ISSN 0964-6906. PMC 6360275. PMID 30358836.
  34. ^ Goold, Robert; Hamilton, Joseph; Menneteau, Thomas; Flower, Michael; Bunting, Emma L.; Aldous, Sarah G.; Porro, Antonio; Vicente, José R.; Allen, Nicholas D.; Wilkinson, Hilary; Bates, Gillian P.; Sartori, Alessandro A.; Thalassinos, Konstantinos; Balmus, Gabriel; Tabrizi, Sarah J. (August 2021). "FAN1 controls mismatch repair complex assembly via MLH1 retention to stabilize CAG repeat expansion in Huntington's disease". Cell Reports. 36 (9): 109649. doi:10.1016/j.celrep.2021.109649. PMC 8424649. PMID 34469738.
  35. ^ Tabrizi, Sarah J.; Flower, Michael D.; Ross, Christopher A.; Wild, Edward J. (October 2020). "Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities". Nature Reviews Neurology. 16 (10): 529–546. doi:10.1038/s41582-020-0389-4. ISSN 1759-4758. PMID 32796930. S2CID 221129777.
  36. ^ Tabrizi, Sarah (May 2016). "The Human Revolution". zeitgeistminds.com.
  37. ^ Gallagher, James (11 December 2017). "Huntington's breakthrough may stop disease". bbc.co.uk.
  38. ^ Devlin, Hannah (11 December 2017). "Excitement as trial shows Huntington's drug could slow progress of disease". guardian.com.
  39. ^ Drew, Liam (2018). "How the gene behind Huntington's disease could be neutralized". Nature. 557 (7707): S39 – S41. Bibcode:2018Natur.557S..39D. doi:10.1038/d41586-018-05176-z. PMID 29844556. S2CID 256768090.
  40. ^ Tabrizi, Sarah J.; Leavitt, Blair R.; Landwehrmeyer, G. Bernhard; Wild, Edward J.; Saft, Carsten; Barker, Roger A.; Blair, Nick F.; Craufurd, David; Priller, Josef (6 May 2019). "Targeting Huntingtin Expression in Patients with Huntington's Disease" (PDF). New England Journal of Medicine. 380 (24): 2307–2316. doi:10.1056/NEJMoa1900907. ISSN 0028-4793. PMID 31059641.
  41. ^ "Full Results from Huntingtin Lowering Antisense Oligonucleotides Trial now published". UCL Queen Square Institute of Neurology. 7 May 2019.
  42. ^ Leavitt, Blair R.; Tabrizi, Sarah J. (27 March 2020). "Antisense oligonucleotides for neurodegeneration". Science. 367 (6485): 1428–1429. Bibcode:2020Sci...367.1428L. doi:10.1126/science.aba4624. ISSN 0036-8075. PMID 32217715. S2CID 214671177.
  43. ^ Tabrizi, Sarah J; Estevez-Fraga, Carlos; van Roon-Mom, Willeke M C; Flower, Michael D; Scahill, Rachael I; Wild, Edward J; Muñoz-Sanjuan, Ignacio; Sampaio, Cristina; Rosser, Anne E; Leavitt, Blair R (July 2022). "Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities". The Lancet Neurology. 21 (7): 645–658. doi:10.1016/S1474-4422(22)00121-1. PMC 7613206. PMID 35716694.
  44. ^ a b Scahill, Rachael I; Zeun, Paul; Osborne-Crowley, Katherine; Johnson, Eileanoir B; Gregory, Sarah; Parker, Christopher; Lowe, Jessica; Nair, Akshay; O'Callaghan, Claire; Langley, Christelle; Papoutsi, Marina (June 2020). "Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis". The Lancet Neurology. 19 (6): 502–512. doi:10.1016/S1474-4422(20)30143-5. PMC 7254065. PMID 32470422.
  45. ^ "Study provides 'vital insights' into best time to treat Huntington's disease". ITV News. 26 May 2020. Retrieved 30 November 2020.
  46. ^ Tabrizi, Sarah J.; Schobel, Scott; Gantman, Emily C.; Mansbach, Alexandra; Borowsky, Beth; Konstantinova, Pavlina; Mestre, Tiago A.; Panagoulias, Jennifer; Ross, Christopher A.; Zauderer, Maurice; Mullin, Ariana P.; Romero, Klaus; Sivakumaran, Sudhir; Turner, Emily C.; Long, Jeffrey D. (July 2022). "A biological classification of Huntington's disease: the Integrated Staging System". The Lancet. Neurology. 21 (7): 632–644. doi:10.1016/S1474-4422(22)00120-X. ISSN 1474-4465. PMID 35716693. S2CID 249682267.
  47. ^ Shetty, Priya (2 June 2012). "Sarah Tabrizi: tracking Huntington's disease". The Lancet. 379 (9831): 2043. doi:10.1016/S0140-6736(12)60884-8. ISSN 0140-6736. PMID 22656876. S2CID 40222846.
  48. ^ Burton, Adrian (2018). "Sarah Tabrizi: Timed to perfection". The Lancet Neurology. 17 (2): 117. doi:10.1016/s1474-4422(17)30303-4. PMID 28916420.
  49. ^ "Sarah J Tabrizi - Google Scholar Citations". scholar.google.co.uk.
  50. ^ https://nam.edu/national-academy-of-medicine-elects-100-new-members-2024//
  51. ^ https://royalsociety.org/news/2024/05/new-fellows-2024/
  52. ^ UCL (5 June 2023). "Professor Sarah Tabrizi receives the 2023 Arvid Carlsson Award". UCL Queen Square Institute of Neurology. Retrieved 5 June 2023.
  53. ^ "MRC announces Millennium Medal winners and Impact Prize finalists". www.ukri.org. 8 December 2022. Retrieved 13 December 2022.
  54. ^ UCL (28 June 2022). "Professor Sarah Tabrizi receives 2022 Osler Medal and HDSA 2022 Research Award". UCL Queen Square Institute of Neurology. Retrieved 20 July 2022.
  55. ^ "Programme and Speakers - AoPGBI". Retrieved 24 June 2022.
  56. ^ UCL (5 November 2019). "Co-Heads of Department awarded Alexander Morison medal in successive years". UCL Queen Square Institute of Neurology. Retrieved 6 November 2019.
  57. ^ UCL (31 October 2019). "Professor Sarah Tabrizi receives Yahr award at World Congress of Neurology 2019". UCL Queen Square Institute of Neurology. Retrieved 6 November 2019.
  58. ^ "Professor Sarah Tabrizi, UCL Queen Square Institute of Neurology, receives the 2018 Cotzias Award". UCL News. 16 November 2018.
  59. ^ Tabrizi, Sarah (19 October 2018). "The NHS at 70 years". ucl.ac.uk.
  60. ^ "UCL News". ucl.ac.uk. 9 November 2017.
  61. ^ "Fellow - Academy of Medical Sciences". www.acmedsci.ac.uk.
  62. ^ "Governance - Wellcome". wellcome.ac.uk.
  63. ^ "Journal of Huntington's Disease". www.iospress.nl. Retrieved 13 June 2016.
Scholia has a profile for Sarah J. Tabrizi (Q24039464).

Read other articles:

Ekklesia (Yunani kuno)

Konstitusi Athena, abad ke-4 SM. Ekklesia (bahasa Yunani Kuno: ἐκκλησία) adalah majelis utama demokrasi di negara-negara kota Yunani kuno. Majelis tersebut merupakan majelis rakyat, terbuka bagi warga laki-laki asalkan memenuhi syarat untuk kewarganegaraan. Referensi Hansen, Mogens Herman; Fischer-Hansen, Tobias (1994), Political Architecture in Archaic and Classical Greek Poleis, dalam Whitehead, David, From Political Architecture to Stephanus Byzantius: Sources for the Ancient ...

 

Nicola Stefanini

Nicola Stefanini Informazioni personali Arbitro di Calcio Sezione Prato Professione Consulente Attività nazionale Anni Campionato Ruolo 2004-20052005-2011 Serie BSerie A e B ArbitroArbitro Premi Anno Premio 2014 Arbitro benemerito Nicola Stefanini (Firenze, 22 gennaio 1975) è un ex arbitro di calcio italiano. In tutte le partite dirette da lui in Serie A, una sola volta c'è stata una vittoria esterna.[1] Carriera Stefanini viene dalla sezione di Prato. Dopo aver totalizzato 37 pre...

 

Gustaf Retzius

Swedish histologist (1842–1919) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Gustaf Retzius – news · newspapers · books · scholar · JSTOR (November 2017) (Learn how and when to remove this template message) Gustaf RetziusGustaf RetziusBorn17 October 1842[1]Stockholm[1]Died21 July 1919(19...

Haftevan

Village in West Azerbaijan province, Iran For other places with a similar name, see Haftvan. Village in West Azerbaijan, IranHaftevan Persian: هفتوانVillageSt. George Church, a 13th century Armenian churchHaftevanCoordinates: 38°10′04″N 44°45′24″E / 38.16778°N 44.75667°E / 38.16778; 44.75667[1]CountryIranProvinceWest AzerbaijanCountySalmasDistrictCentralRural DistrictZulachayPopulation (2016)[2] • Total8,203Time zoneUT...

 

A Tale of Two Cities (1917 film)

1917 American filmA Tale of Two CitiesDirected byFrank LloydWritten byFrank LloydBased onA Tale of Two Cities1859 novelby Charles DickensStarringWilliam Farnum Jewel Carmen Charles Clary Herschel MayallCinematographyWilliam C. Foster George SchneidermanProductioncompanyFox Film CorporationDistributed byFox Film CorporationRelease date March 11, 1917 (1917-03-11) Running time70 minutesCountryUnited StatesLanguageSilent (English intertitles) A Tale of Two Cities A Tale of Two Cit...

 

Shannon Woodward

Shannon WoodwardShannon Woodward speaking at the 2017 San Diego Comic-Con InternationalLahirShannon Marie Woodward17 Desember 1984 (umur 39)Phoenix, ArizonaPekerjaanAktrisTahun aktif1991–sekarang Shannon Marie Woodward (lahir 17 Desember 1984) adalah aktris Amerika Serikat yang dikenal sebagai pemeran Sabrina di Raising Hope dan Di Di Malloy di The Riches. Woodward saat ini memerankan Elsie Hughes, seorang programer, di seri TV Westworld yang ditayangkan di HBO.[1] Filmog...

National Land Survey of Finland

National Land Survey of FinlandMaanmittauslaitosLantmäteriverketAgency overviewFormed1812 (1812)JurisdictionGovernment of FinlandHeadquartersOpastinsilta 12 C, Helsinki60°11′57″N 024°56′11″E / 60.19917°N 24.93639°E / 60.19917; 24.93639Employees1,761Annual budget€127 million (2010)Agency executiveArvo Kokkonen, Director GeneralParent agencyMinistry of Agriculture and ForestryWebsitewww.maanmittauslaitos.fi/en Footnotes[1][2] The Natio...

 

Carson River

This article is about the river in Nevada. For the river in Australia, see Carson River (Western Australia). River in Nevada, United States Carson RiverToinahukwa (Northern Paiute)Watahshemu (Washo)Carson River at Dayton, NevadaCarson River BasinEtymologyKit CarsonNative nameToinahukwa[1] (Northern Paiute)Watahshemu[2] (Washo)LocationCountryUnited StatesStateNevadaRegioncentral Lahontan regionPhysical characteristicsSourceWest Fork Carson River &#...

 

Imitasi Kristus

Yesus Mengajar dengan Para Muridnya, James Tissot, s. 1890 Dalam teologi Kristen, imitasi Kristus adalah praktek mengikuti contoh Yesus.[1][2][3] Di Gereja Timur, istilah kehidupan dalam Kristus terkadang dipakai untuk konsep yang sama.[1] Gagasan imigtasi Kristus telah menjadi unsur penting etika Kristen dan spiritualitas.[4] Rujukan-rujukan untuk konsep tersebut dan prakteknya ditemukan dalam dokumen-dokumen Kristen terawal, seperti surat-surat Paulus...

List of international goals scored by Romelu Lukaku

Lukaku celebrating his first goal against Tunisia at the 2018 FIFA World Cup Romelu Lukaku is a Belgian professional footballer who represents the Belgium national football team as a striker. Aged 17, he made his debut for his country in a 1–0 defeat to Croatia in Brussels in March 2010. His first and second international goals came on his eighth appearance for Belgium, in a 2–0 friendly victory over Russia. As of 26 March 2024[update], Lukaku is his country's top score...

 

Shinzan Miyamae Roshi

Shinzan Miyamae RoshiTitleRōshiPersonalBornJunichi Miyamae1935 (1935)Niigata, JapanDiedMay 27, 2021(2021-05-27) (aged 85–86)[citation needed]ReligionZen BuddhismNationalityJapaneseSchoolRinzai (Zendo Kyodan)LineageInzanSenior posting Students Ven. Geshin Unsan, John Wittmayer (Shinko Jion) Melody Cornell Eshin Roshi (Shinzan’s dharma heir), Julian Daizan Skinner Rōshi, Matt Shinkai Kane, Barbara Jikai Gabrys, Tomio Yugaku Ameku Part of a series onZen Buddhism Main arti...

 

The Sleeze Brothers

The Sleeze BrothersSleeze Brothers, issue #1, Epic Comics UK.Publication informationPublisherMarvel ComicsScheduleMonthlyFormatLimited seriesGenreScience fiction comedyPublication dateJune 1989 – January 1990No. of issues6Creative teamWritten byJohn CarnellArtist(s)Andy Lanning The Sleeze Brothers was a comic book limited series published by Marvel's Epic Comics imprint, between August 1989 and January 1990 (UK release dates), lasting for 6 issues. A collection of the six issues were l...

Mainland Japan

Political term in Imperial Japan Mainland JapanNative name: 内地Passports for passengers between Mainland Japan and Okinawa during 1952–1972.GeographyLocationJapanDemographicsEthnic groupsJapanese peopleAinu peopleRyukyuan people Mainland Japan (内地, naichi, lit. inner lands) is a term used to distinguish Japan's core land area from its outlying territories. It is most commonly used to distinguish the country's four largest islands (Hokkaidō, Honshū, Kyūshū and Shikoku) from smalle...

 

Nefele

Hukuman Iksion; Nefele duduk di kaki Merkurius (Hermes). Lukisan dinding Romawi di Pompeii. Dalam mitologi Yunani, Nefele (bahasa Yunani: Νεφέλη, dari νέφος nephos awan) adalah nimfa atau dewi awan. Nefele merupakan tokoh penting dalam kisah Friksos dan Helle.[1] Zeus menciptakan Nefele dari awan dalam wujud yang menyerupai Hera. Zeus menciptakan Nefele untuk menguji Iksion, yang dicurigai oleh Zeus berhasrat pada Hera. Iksion melihat Nefele dan mengiranya sebagai Hera....

 

Pollination

Biological process occurring in plants Diagram illustrating the process of pollination Female carpenter bee with pollen collected from a night-blooming cereusPollination is the transfer of pollen from an anther of a plant to the stigma of a plant, later enabling fertilisation and the production of seeds.[1] Pollinating agents can be animals such as insects, for example beetles or butterflies; birds, and bats; water; wind; and even plants themselves. Pollinating animals travel from pla...

West Japan Railway Company

Japanese railway company Not to be confused with Nishi-Nippon Railroad, which has a similar Japanese name. JR West redirects here. For the American politician, see J. R. West. This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: West Japan Railway Company – news · newspapers · books · scholar · JSTOR (November 2022) (Learn how and when to remove this message...

 

Jeong Chan

Jeong ChanLahir23 Februari 1971 (umur 53)Seoul, Korea SelatanNama lainJung ChanTahun aktif1994–sekarangNama KoreaHangul정찬 Hanja鄭燦 Alih AksaraJeong ChanMcCune–ReischauerChǒng Ch'an Jeong Chan (juga dieja Jung Chan; lahir 23 Februari 1971) adalah aktor asal Korea Selatan. Filmografi Film The Young Man (1994) Over the Rainbow (2002) Road Movie (2002) Spring Breeze (2003) Invisible Light (2004) Possible Changes (2004) Woman on the Beach (2006) The Cut (2007) Serial TV...

 

العلاقات الأرمنية الهندية

العلاقات الأرمينية الهندية أرمينيا الهند   أرمينيا   الهند تعديل مصدري - تعديل   العلاقات الأرمينية الهندية هي العلاقات الثنائية التي تجمع بين أرمينيا والهند.[1][2][3][4][5] مقارنة بين البلدين هذه مقارنة عامة ومرجعية للدولتين: وجه المقارنة أرم�...

Kickle Cubicle

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: Kickle Cubicle – news · newspapers · books · scholar · JSTOR (November 2006) (Learn how and when to remove this message) 1988 video gameKickle CubiclePAL region box artDeveloper(s)IremPublisher(s)JP/NA: IremEU: Nintendo (NES)Platform(s)Arcade, Nintendo Entertai...

 

Luis Alfageme

Luis AlfagemeNazionalità Argentina Altezza190 cm Peso80 kg Calcio RuoloAttaccante Squadra Terni Football Club CarrieraGiovanili  Cipolletti Boca Juniors2003-2004 Brescia2004-2005→  Køge BK Squadre di club1 2005-2006→  Acireale26 (5)[1]2006-2007 Brescia6 (0)2007→  Cremonese10 (0)2007-2008→  Pescara10 (1)2008→  Sambenedettese6 (0)2008-2009→  Virtus Lanciano28 (3)[2]2009-2012 Grosseto74 (11)2012-2014 T...